256 related articles for article (PubMed ID: 31243239)
21. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer.
Ishibuchi K; Iwakura T; Kaneko M; Fukasawa H; Furuya R
CEN Case Rep; 2020 Aug; 9(3):215-219. PubMed ID: 32170578
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.
Fujita T; Hayama N; Kuroki T; Shiraishi Y; Amano H; Nakamura M; Hirano S; Aramaki N; Ichinose S; Shimizu S; Tabeta H; Nakamura S
Thorac Cancer; 2019 Nov; 10(11):2179-2182. PubMed ID: 31512401
[TBL] [Abstract][Full Text] [Related]
24. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
25. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
[TBL] [Abstract][Full Text] [Related]
26. Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Takahashi T; Tateishi A; Bychkov A; Fukuoka J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130676
[TBL] [Abstract][Full Text] [Related]
27. An unknown reaction to pembrolizumab: giant cell arteritis.
Micaily I; Chernoff M
Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
[No Abstract] [Full Text] [Related]
28. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
29. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
30. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L
Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639
[TBL] [Abstract][Full Text] [Related]
31. New drugs and new toxicities: pembrolizumab-induced myocarditis.
Inayat F; Masab M; Gupta S; Ullah W
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367376
[TBL] [Abstract][Full Text] [Related]
32. Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review.
Atallah-Yunes SA; Kadado AJ; Soe MH
Curr Probl Cancer; 2019 Oct; 43(5):504-510. PubMed ID: 30685067
[TBL] [Abstract][Full Text] [Related]
33. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
34. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Kian W; Zemel M; Elobra F; Sharb AA; Levitas D; Assabag Y; Alguayn F; Yakobson A; Rouvinov K; Fuchs L
Anticancer Drugs; 2022 Jan; 33(1):e738-e740. PubMed ID: 34321417
[TBL] [Abstract][Full Text] [Related]
35. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
36. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
[TBL] [Abstract][Full Text] [Related]
37. Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review.
Khaddour K; Singh V; Shayuk M
BMC Cancer; 2019 May; 19(1):449. PubMed ID: 31088420
[TBL] [Abstract][Full Text] [Related]
38. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
40. Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
Zhang D; Zhang Y; Huang Y; Kong L; Yu J
Lung Cancer; 2020 Jan; 139():18-21. PubMed ID: 31704279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
